[ET Net News Agency, 5 February 2024] CCB International lowered the target price for
RemeGen (09995) to HKD26 from HK$49.3 and maintained the "outperform" rating.
The research house said it lowers 2023F/2024F/2025F revenue forecast by 3%/2%/2%,
bringing it to RMB1.1b/1.7b/2.2b. (RC)